Silo Pharma Inc. has announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 17/954,858, titled "Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders." This patent, licensed from Columbia University, will strengthen the intellectual property protection for Silo's lead asset, SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD). The patent is expected to be issued as U.S. Patent No. 12,329,726 on June 17, 2025. According to Eric Weisblum, CEO of Silo, this development enhances protection for the key technology behind their novel PTSD prophylactic, which is being prepared for Phase 1 clinical trials.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.